×
Surrozen Total Liabilities 2021-2025 | SRZN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Surrozen total liabilities from 2021 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
View More
Surrozen Total Liabilities 2021-2025 | SRZN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Surrozen total liabilities from 2021 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$76.3B
Zoetis (ZTS)
$66.2B
Takeda Pharmaceutical (TAK)
$45.9B
Daiichi Sankyo, - (DSNKY)
$45.5B
BeOne Medicines - (ONC)
$32.3B
Sandoz Group AG (SDZNY)
$25B
Summit Therapeutics (SMMT)
$19.5B
Merck (MKKGY)
$16.7B
Shionogi (SGIOY)
$14.2B
United Therapeutics (UTHR)
$13.2B
Neurocrine Biosciences (NBIX)
$13.1B
Orion OYJ (ORINY)
$11B
IPSEN (IPSEY)
$10.5B
Stevanato Group S.p.A (STVN)
$7.5B
Corcept Therapeutics (CORT)
$7.5B
Madrigal Pharmaceuticals (MDGL)
$7.4B
Grifols, S.A (GRFS)
$6.8B
Ionis Pharmaceuticals (IONS)
$6.6B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.4B
Hypermarcas (HYPMY)
$3.1B
Crinetics Pharmaceuticals (CRNX)
$2.9B
Catalyst Pharmaceuticals (CPRX)
$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.5B
NewAmsterdam Pharma (NAMS)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.1B
Ocular Therapeutix (OCUL)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.8B
ARS Pharmaceuticals (SPRY)
$1.8B